Danielle B. Rice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Danielle B. Rice has a total of 467 co-authors. Here are the top co-authors by number of shared publications:
- Brett D. Thombs
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
13 shared publications - David Moher
Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
11 shared publications Becky Skidmore
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
5 shared publications- Brian Hutton
Ottawa Hospital Research Institute Ottawa Hospital Ottawa Ontario Canada
5 shared publications - Andrea Benedetti
McGill University
4 shared publications - Brooke Levis
Department of Epidemiology Biostatistics and Occupational Health, McGill University Montréal Québec Canada
4 shared publications
Latest Publications
- Open Access
Mental health symptom changes by sex or gender during COVID-19 compared to pre-pandemic: a systematic review and meta-analysis update
KEY POINTS: Question: Did changes in mental health symptoms from pre-COVID-19 to during the pandemic differ by sex or gender? Findings: In this systematic review and meta-analysis study of findings from 27 unique cohorts, changes from before to during the COVID-19 pandemic in mental health symptoms, including general mental health, anxiety, depression, and stress, were not statistically significantly different by sex or gender. Meaning: There were not likely substantial sex and gender differences in mental health symptom changes during the COVID-19 pandemic. Importance: Concerns remain about whether COVID-19 affected mental health differently across sex or gender groups. We previously reported that changes in general mental health and anxiety symptoms, but not depression or stress, worsened more for females or women than males or men, but that was based on 12 studies published up to August 2021. Objective: To investigate the sex or gender differences in mental health symptoms before and during the COVID-19 pandemic with updated evidence. Data Sources: MEDLINE, PsycINFO, CINAHL, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang, medRxiv, Open Science Framework Preprints searched to August 31, 2023. Study Selection: Eligible studies included change data for general mental health, anxiety symptoms, depression symptoms, or stress from pre-to during COVID-19 by sex or gender. Two independent reviewers reviewed citations for eligibility. Data Extraction and Synthesis: Standardized mean differences (SMDs) were extracted for changes of continuous outcomes and proportions for dichotomous outcomes. Two independent reviewers completed data extraction and risk of bias assessment with an adapted Joanna Briggs Institute Checklist for Prevalence Studies. Data were pooled by random-effects models. Main Outcomes and Measures: Difference in change of SMDs and proportions between sex or gender groups pre-COVID-19 to COVID-19. Results: We included data from 27 unique cohorts (N = 102 to 18,127). Change differences by sex or gender were minimal and not statistically significant: general mental health (SMD change women-men = 0.01, 95% confidence interval [CI]:-0.07 to 0.10; proportion change women-men = −0.03, 95% CI: −0.08 to 0.03), anxiety (SMD change women-men = 0.09, 95% CI −0.04 to 0.22; proportion change women-men = −0.05, 95% CI: −0.20 to 0.11), depression (SMD change women-men = 0.10, 95% CI: −0.00 to 0.20; proportion change women-men = −0.13, 95% CI: −0.81 to 0.55), and stress (SMD change women-men = −0.08, 95% CI −0.16 to 0.01, proportion change women-men = 0.04, 95% CI −0.10 to 0.17). No studies reported eligible mental health outcomes for gender minorities. Conclusion and Relevance: We found no significant sex or gender differences in mental health changes. Future research should report outcomes for gender minority groups, even if small numbers, to support evidence synthesis. Registration: PROSPERO (CRD42020179703)
Open AccessMental health symptom changes by sex or gender during COVID-19 compared to pre-pandemic: a systematic review and meta-analysis update
KEY POINTS: Question: Did changes in mental health symptoms from pre-COVID-19 to during the pandemic differ by sex or gender? Findings: In this systematic review and meta-analysis study of findings from 27 unique cohorts, changes from before to during the COVID-19 pandemic in mental health symptoms, including general mental health, anxiety, depression, and stress, were not statistically significantly different by sex or gender. Meaning: There were not likely substantial sex and gender differences in mental health symptom changes during the COVID-19 pandemic. Importance: Concerns remain about whether COVID-19 affected mental health differently across sex or gender groups. We previously reported that changes in general mental health and anxiety symptoms, but not depression or stress, worsened more for females or women than males or men, but that was based on 12 studies published up to August 2021. Objective: To investigate the sex or gender differences in mental health symptoms before and during the COVID-19 pandemic with updated evidence. Data Sources: MEDLINE, PsycINFO, CINAHL, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang, medRxiv, Open Science Framework Preprints searched to August 31, 2023. Study Selection: Eligible studies included change data for general mental health, anxiety symptoms, depression symptoms, or stress from pre-to during COVID-19 by sex or gender. Two independent reviewers reviewed citations for eligibility. Data Extraction and Synthesis: Standardized mean differences (SMDs) were extracted for changes of continuous outcomes and proportions for dichotomous outcomes. Two independent reviewers completed data extraction and risk of bias assessment with an adapted Joanna Briggs Institute Checklist for Prevalence Studies. Data were pooled by random-effects models. Main Outcomes and Measures: Difference in change of SMDs and proportions between sex or gender groups pre-COVID-19 to COVID-19. Results: We included data from 27 unique cohorts (N = 102 to 18,127). Change differences by sex or gender were minimal and not statistically significant: general mental health (SMD change women-men = 0.01, 95% confidence interval [CI]:-0.07 to 0.10; proportion change women-men = −0.03, 95% CI: −0.08 to 0.03), anxiety (SMD change women-men = 0.09, 95% CI −0.04 to 0.22; proportion change women-men = −0.05, 95% CI: −0.20 to 0.11), depression (SMD change women-men = 0.10, 95% CI: −0.00 to 0.20; proportion change women-men = −0.13, 95% CI: −0.81 to 0.55), and stress (SMD change women-men = −0.08, 95% CI −0.16 to 0.01, proportion change women-men = 0.04, 95% CI −0.10 to 0.17). No studies reported eligible mental health outcomes for gender minorities. Conclusion and Relevance: We found no significant sex or gender differences in mental health changes. Future research should report outcomes for gender minority groups, even if small numbers, to support evidence synthesis. Registration: PROSPERO (CRD42020179703)
- Open Access
Dissemination of study results to participants in mental health research: a meta-research review of studies published in high-impact psychiatry journals
Objectives: We surveyed authors of publications in high-impact psychiatry journals to assess the (1) proportion that disseminated results to study participants or others with lived experience, and, among those who disseminated, (2) methods (eg, email) and (3) tools (eg, plain-language summary) used. Design: Meta-research review. Data source: PubMed search on 14 December 2022 and emails to study authors for information on dissemination. Eligibility criteria: Eligible studies collected primary human data and were published in psychiatry journals with 2021 impact factor ≥10. Data extraction and synthesis: Study information was extracted by one investigator and validated by a second investigator, with conflicts resolved by consensus, with a third investigator consulted as necessary. We emailed authors approximately 2 years post-publication to ensure sufficient time had passed to share results. We estimated the proportion of authors that may have disseminated results to participants or others with lived experience, assuming that non-respondents (1) did not disseminate, (2) were half as likely to disseminate as respondents or (3) disseminated in the same proportion as respondents. Results: Of 141 studies, 94 (67%) authors responded. Among respondents, 21 (22%) reported disseminating to study participants, and an additional 9 (10%) reported disseminating lay materials to people with lived experience (total of 30 studies, 32%). Overall, we estimated that 15% (95% CI 10% to 22%) to 23% (95% CI 17% to 30%) of authors may have disseminated results directly to study participants and 21% (95% CI 15% to 29%) to 32% (95% CI 25% to 40%) to participants or others with lived experience. Among the 30 that reported disseminating, the most common methods were sending mail or emails to study participants (17 studies, 57%) and posting on social media (15 studies, 50%). The most common tools were plain-language summaries (22 studies, 73%) and webinars or other meetings (15 studies, 50%). Conclusions: Dissemination of results to participants in mental health research is uncommon. Funding agencies, ethics committees, journals and academic institutions should support dissemination.
Open AccessDissemination of study results to participants in mental health research: a meta-research review of studies published in high-impact psychiatry journals
Objectives: We surveyed authors of publications in high-impact psychiatry journals to assess the (1) proportion that disseminated results to study participants or others with lived experience, and, among those who disseminated, (2) methods (eg, email) and (3) tools (eg, plain-language summary) used. Design: Meta-research review. Data source: PubMed search on 14 December 2022 and emails to study authors for information on dissemination. Eligibility criteria: Eligible studies collected primary human data and were published in psychiatry journals with 2021 impact factor ≥10. Data extraction and synthesis: Study information was extracted by one investigator and validated by a second investigator, with conflicts resolved by consensus, with a third investigator consulted as necessary. We emailed authors approximately 2 years post-publication to ensure sufficient time had passed to share results. We estimated the proportion of authors that may have disseminated results to participants or others with lived experience, assuming that non-respondents (1) did not disseminate, (2) were half as likely to disseminate as respondents or (3) disseminated in the same proportion as respondents. Results: Of 141 studies, 94 (67%) authors responded. Among respondents, 21 (22%) reported disseminating to study participants, and an additional 9 (10%) reported disseminating lay materials to people with lived experience (total of 30 studies, 32%). Overall, we estimated that 15% (95% CI 10% to 22%) to 23% (95% CI 17% to 30%) of authors may have disseminated results directly to study participants and 21% (95% CI 15% to 29%) to 32% (95% CI 25% to 40%) to participants or others with lived experience. Among the 30 that reported disseminating, the most common methods were sending mail or emails to study participants (17 studies, 57%) and posting on social media (15 studies, 50%). The most common tools were plain-language summaries (22 studies, 73%) and webinars or other meetings (15 studies, 50%). Conclusions: Dissemination of results to participants in mental health research is uncommon. Funding agencies, ethics committees, journals and academic institutions should support dissemination.
- Open Access
- 8 November 2025
- Published by Elsevier in Health Policy
- Vol. 163, 105485
Co-developing an inclusive interprofessional health workforce minimum data standard for enhanced planning and decision-making: A Canadian case with international relevance
- 8 November 2025
- Published by Elsevier in Health Policy
- Vol. 163, 105485
Open AccessCo-developing an inclusive interprofessional health workforce minimum data standard for enhanced planning and decision-making: A Canadian case with international relevance
- Open Access
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64801
Implementation and Effectiveness of the Power Over Pain Portal for Patients Awaiting a Tertiary Care Consultation for Chronic Pain: Protocol for a Pilot, Prospective, Cohort, Mixed Methods Study
Background: Chronic pain (CP) affects approximately 8 million people in Canada. Access to CP care is challenging, and there is no robust monitoring system to support patient care and decision-making. The Power Over Pain (POP) Portal was developed by people living with CP, health care providers, researchers, health system decision-makers, policymakers, and community partners to address these concerns. The POP Portal is a comprehensive web-based platform that provides rapid access to a continuum of free, evidence-informed resources for the self-management of CP, mental health, and substance use health. The POP Portal also offers self-assessment tools that enable users to track their progress and receive personalized recommendations. Objective: This hybrid implementation-effectiveness type III pilot study aimed to determine the feasibility (ie, recruitment, integration, facilitators and barriers, patient engagement, usability, and acceptability) of the POP Portal’s implementation for people waiting for care at a tertiary pain clinic. Methods: A cohort of 80 adults living with pain was recruited from the waitlist of a tertiary care pain clinic over a 3-month period. Following an orientation on the POP Portal, participants were encouraged to use it according to their needs and preferences. They were also asked to complete questionnaires at baseline (0 months) and the 3-month follow-up. Primary feasibility measures included recruitment and retention rates and portal acceptability using the Acceptability E-scale. We also measured usability using the System Usability Scale, evaluated engagement through portal analytics, and identified facilitators and barriers via semistructured interviews with 12 to 15 study participants. These interviews further assessed the acceptability and usability of the portal for participants. Exploratory measures included pain severity, pain-related interference, self-efficacy, coping strategies, and symptoms of anxiety and depression. Results: We will present descriptive data on the cohort’s sex and gender, age, rural or urban status, and ethnic background, as well as the acceptability, usability, and feasibility of the portal. Measures of central tendency will be reported for continuous variables, and frequencies and proportions will be reported for categorical variables. We will also present change in clinical outcomes across time and a synthesis of qualitative and thematic data. Conclusions: We anticipate that most patients awaiting care at a tertiary pain clinic recruited will use the POP Portal and find it to be acceptable for addressing some of their pain and associated health concerns. If the feasibility of recruiting and retaining patients is demonstrated as anticipated, we will be able to move forward with a multisite study to evaluate the implementation and effectiveness of the POP Portal among patients waiting for a tertiary care consultation. International Registered Report Identifier (IRRID): DERR1-10.2196/64801
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e64801
Open AccessImplementation and Effectiveness of the Power Over Pain Portal for Patients Awaiting a Tertiary Care Consultation for Chronic Pain: Protocol for a Pilot, Prospective, Cohort, Mixed Methods Study
Background: Chronic pain (CP) affects approximately 8 million people in Canada. Access to CP care is challenging, and there is no robust monitoring system to support patient care and decision-making. The Power Over Pain (POP) Portal was developed by people living with CP, health care providers, researchers, health system decision-makers, policymakers, and community partners to address these concerns. The POP Portal is a comprehensive web-based platform that provides rapid access to a continuum of free, evidence-informed resources for the self-management of CP, mental health, and substance use health. The POP Portal also offers self-assessment tools that enable users to track their progress and receive personalized recommendations. Objective: This hybrid implementation-effectiveness type III pilot study aimed to determine the feasibility (ie, recruitment, integration, facilitators and barriers, patient engagement, usability, and acceptability) of the POP Portal’s implementation for people waiting for care at a tertiary pain clinic. Methods: A cohort of 80 adults living with pain was recruited from the waitlist of a tertiary care pain clinic over a 3-month period. Following an orientation on the POP Portal, participants were encouraged to use it according to their needs and preferences. They were also asked to complete questionnaires at baseline (0 months) and the 3-month follow-up. Primary feasibility measures included recruitment and retention rates and portal acceptability using the Acceptability E-scale. We also measured usability using the System Usability Scale, evaluated engagement through portal analytics, and identified facilitators and barriers via semistructured interviews with 12 to 15 study participants. These interviews further assessed the acceptability and usability of the portal for participants. Exploratory measures included pain severity, pain-related interference, self-efficacy, coping strategies, and symptoms of anxiety and depression. Results: We will present descriptive data on the cohort’s sex and gender, age, rural or urban status, and ethnic background, as well as the acceptability, usability, and feasibility of the portal. Measures of central tendency will be reported for continuous variables, and frequencies and proportions will be reported for categorical variables. We will also present change in clinical outcomes across time and a synthesis of qualitative and thematic data. Conclusions: We anticipate that most patients awaiting care at a tertiary pain clinic recruited will use the POP Portal and find it to be acceptable for addressing some of their pain and associated health concerns. If the feasibility of recruiting and retaining patients is demonstrated as anticipated, we will be able to move forward with a multisite study to evaluate the implementation and effectiveness of the POP Portal among patients waiting for a tertiary care consultation. International Registered Report Identifier (IRRID): DERR1-10.2196/64801
- Open Access
- 31 July 2025
- Published by Taylor & Francis in Canadian Journal of Pain
- Vol. 9 (1) , 2499553
Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review
Opioid use disorder (OUD) is a growing public health concern in North America, often coexisting with chronic noncancer pain (CNCP). Managing both conditions presents unique challenges, highlighting the need for evidence to guide decision making. The study aimed to conduct a systematic review that summarizes evidence on the efficacy, effectiveness, and safety of opioid analgesics alone or in combination with opioid agonist therapy (OAT) to manage CNCP in people with OUD or with a history of OUD. We searched MEDLINE, Embase, PsycINFO, CINAHL and AMED from inception to July 2023 for randomized studies and up to January 2025 for non-randomized studies that explored the efficacy, effectiveness, and safety of opioids for people living with chronic pain and current or prior OUD. We assessed the risk of bias in included studies, evaluated the quality of evidence using the GRADE approach, and provided a narrative summary of treatment effects. Our search identified 15,988 unique citations, of which six observational studies were deemed eligible to inform safety outcomes for review, while no observational studies or RCTs met the eligibility criteria for efficacy or effectiveness outcomes. The likelihood of suicidality was twice as high in CNCP patients with OUD receiving long-term opioid analgesics compared to those without OUD (absolute risk increase: 127; 95% CI: 36 to 249 more participants with suicidality in 1,000 participants; moderate certainty evidence). Compared to opioid analgesics alone, the risk of fatal opioid-related overdose may decrease in patients with CNCP and OUD who receive both opioid analgesics and OAT (absolute risk reduction: 60; 95%CI: 18 to 94 fewer deaths in 1,000 participants; low certainty evidence). There is a paucity of evidence to inform practice and policy regarding opioid analgesic prescribing amongst people with OUD. Existing evidence suggests that such prescribing is associated with a higher risk of suicidality, while the use of OAT together with opioid analgesics in this population may be protective against fatal overdose. Further observational and trial research is needed to clarify the benefits and harms of opioid analgesics for CNCP patients with OUD.
- 31 July 2025
- Published by Taylor & Francis in Canadian Journal of Pain
- Vol. 9 (1) , 2499553
Open AccessOpioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review
Opioid use disorder (OUD) is a growing public health concern in North America, often coexisting with chronic noncancer pain (CNCP). Managing both conditions presents unique challenges, highlighting the need for evidence to guide decision making. The study aimed to conduct a systematic review that summarizes evidence on the efficacy, effectiveness, and safety of opioid analgesics alone or in combination with opioid agonist therapy (OAT) to manage CNCP in people with OUD or with a history of OUD. We searched MEDLINE, Embase, PsycINFO, CINAHL and AMED from inception to July 2023 for randomized studies and up to January 2025 for non-randomized studies that explored the efficacy, effectiveness, and safety of opioids for people living with chronic pain and current or prior OUD. We assessed the risk of bias in included studies, evaluated the quality of evidence using the GRADE approach, and provided a narrative summary of treatment effects. Our search identified 15,988 unique citations, of which six observational studies were deemed eligible to inform safety outcomes for review, while no observational studies or RCTs met the eligibility criteria for efficacy or effectiveness outcomes. The likelihood of suicidality was twice as high in CNCP patients with OUD receiving long-term opioid analgesics compared to those without OUD (absolute risk increase: 127; 95% CI: 36 to 249 more participants with suicidality in 1,000 participants; moderate certainty evidence). Compared to opioid analgesics alone, the risk of fatal opioid-related overdose may decrease in patients with CNCP and OUD who receive both opioid analgesics and OAT (absolute risk reduction: 60; 95%CI: 18 to 94 fewer deaths in 1,000 participants; low certainty evidence). There is a paucity of evidence to inform practice and policy regarding opioid analgesic prescribing amongst people with OUD. Existing evidence suggests that such prescribing is associated with a higher risk of suicidality, while the use of OAT together with opioid analgesics in this population may be protective against fatal overdose. Further observational and trial research is needed to clarify the benefits and harms of opioid analgesics for CNCP patients with OUD.
- Open Access
- 26 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Implementation and Effectiveness of the Power Over Pain Portal for Patients Awaiting a Tertiary Care Consultation for Chronic Pain: Protocol for a Pilot, Prospective, Cohort, Mixed Methods Study (Preprint)
BACKGROUND Chronic pain (CP) affects approximately 8 million people in Canada. Access to CP care is challenging, and there is no robust monitoring system to support patient care and decision-making. The Power Over Pain (POP) Portal was developed by people living with CP, health care providers, researchers, health system decision-makers, policymakers, and community partners to address these concerns. The POP Portal is a comprehensive web-based platform that provides rapid access to a continuum of free, evidence-informed resources for the self-management of CP, mental health, and substance use health. The POP Portal also offers self-assessment tools that enable users to track their progress and receive personalized recommendations. OBJECTIVE This hybrid implementation-effectiveness type III pilot study aimed to determine the feasibility (ie, recruitment, integration, facilitators and barriers, patient engagement, usability, and acceptability) of the POP Portal’s implementation for people waiting for care at a tertiary pain clinic. METHODS A cohort of 80 adults living with pain was recruited from the waitlist of a tertiary care pain clinic over a 3-month period. Following an orientation on the POP Portal, participants were encouraged to use it according to their needs and preferences. They were also asked to complete questionnaires at baseline (0 months) and the 3-month follow-up. Primary feasibility measures included recruitment and retention rates and portal acceptability using the Acceptability E-scale. We also measured usability using the System Usability Scale, evaluated engagement through portal analytics, and identified facilitators and barriers via semistructured interviews with 12 to 15 study participants. These interviews further assessed the acceptability and usability of the portal for participants. Exploratory measures included pain severity, pain-related interference, self-efficacy, coping strategies, and symptoms of anxiety and depression. RESULTS We will present descriptive data on the cohort’s sex and gender, age, rural or urban status, and ethnic background, as well as the acceptability, usability, and feasibility of the portal. Measures of central tendency will be reported for continuous variables, and frequencies and proportions will be reported for categorical variables. We will also present change in clinical outcomes across time and a synthesis of qualitative and thematic data. CONCLUSIONS We anticipate that most patients awaiting care at a tertiary pain clinic recruited will use the POP Portal and find it to be acceptable for addressing some of their pain and associated health concerns. If the feasibility of recruiting and retaining patients is demonstrated as anticipated, we will be able to move forward with a multisite study to evaluate the implementation and effectiveness of the POP Portal among patients waiting for a tertiary care consultation. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/64801
- 26 July 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementation and Effectiveness of the Power Over Pain Portal for Patients Awaiting a Tertiary Care Consultation for Chronic Pain: Protocol for a Pilot, Prospective, Cohort, Mixed Methods Study (Preprint)
BACKGROUND Chronic pain (CP) affects approximately 8 million people in Canada. Access to CP care is challenging, and there is no robust monitoring system to support patient care and decision-making. The Power Over Pain (POP) Portal was developed by people living with CP, health care providers, researchers, health system decision-makers, policymakers, and community partners to address these concerns. The POP Portal is a comprehensive web-based platform that provides rapid access to a continuum of free, evidence-informed resources for the self-management of CP, mental health, and substance use health. The POP Portal also offers self-assessment tools that enable users to track their progress and receive personalized recommendations. OBJECTIVE This hybrid implementation-effectiveness type III pilot study aimed to determine the feasibility (ie, recruitment, integration, facilitators and barriers, patient engagement, usability, and acceptability) of the POP Portal’s implementation for people waiting for care at a tertiary pain clinic. METHODS A cohort of 80 adults living with pain was recruited from the waitlist of a tertiary care pain clinic over a 3-month period. Following an orientation on the POP Portal, participants were encouraged to use it according to their needs and preferences. They were also asked to complete questionnaires at baseline (0 months) and the 3-month follow-up. Primary feasibility measures included recruitment and retention rates and portal acceptability using the Acceptability E-scale. We also measured usability using the System Usability Scale, evaluated engagement through portal analytics, and identified facilitators and barriers via semistructured interviews with 12 to 15 study participants. These interviews further assessed the acceptability and usability of the portal for participants. Exploratory measures included pain severity, pain-related interference, self-efficacy, coping strategies, and symptoms of anxiety and depression. RESULTS We will present descriptive data on the cohort’s sex and gender, age, rural or urban status, and ethnic background, as well as the acceptability, usability, and feasibility of the portal. Measures of central tendency will be reported for continuous variables, and frequencies and proportions will be reported for categorical variables. We will also present change in clinical outcomes across time and a synthesis of qualitative and thematic data. CONCLUSIONS We anticipate that most patients awaiting care at a tertiary pain clinic recruited will use the POP Portal and find it to be acceptable for addressing some of their pain and associated health concerns. If the feasibility of recruiting and retaining patients is demonstrated as anticipated, we will be able to move forward with a multisite study to evaluate the implementation and effectiveness of the POP Portal among patients waiting for a tertiary care consultation. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/64801
- Open Access
Safety of influenza vaccination during pregnancy: a systematic review
Objective We conducted a systematic review to evaluate associations between influenza vaccination during pregnancy and adverse birth outcomes and maternal non-obstetric serious adverse events (SAEs), taking into consideration confounding and temporal biases. Methods Electronic databases (Ovid MEDLINE ALL, Embase Classic+Embase and the Cochrane Central Register of Controlled Trials) were searched to June 2021 for observational studies assessing associations between influenza vaccination during pregnancy and maternal non-obstetric SAEs and adverse birth outcomes, including preterm birth, spontaneous abortion, stillbirth, small-for-gestational-age birth and congenital anomalies. Studies of live attenuated vaccines, single-arm cohort studies and abstract-only publications were excluded. Records were screened using a liberal accelerated approach initially, followed by a dual independent approach for full-text screening, data extraction and risk of bias assessment. Pairwise meta-analyses were conducted, where two or more studies met methodological criteria for inclusion. The Grading of Recommendations, Assessment, Development and Evaluation approach was used to assess evidence certainty. Results Of 9443 records screened, 63 studies were included. Twenty-nine studies (24 cohort and 5 case–control) evaluated seasonal influenza vaccination (trivalent and/or quadrivalent) versus no vaccination and were the focus of our prioritised syntheses; 34 studies of pandemic vaccines (2009 A/H1N1 and others), combinations of pandemic and seasonal vaccines, and seasonal versus seasonal vaccines were also reviewed. Control for confounding and temporal biases was inconsistent across studies, limiting pooling of data. Meta-analyses for preterm birth, spontaneous abortion and small-for-gestational-age birth demonstrated no significant associations with seasonal influenza vaccination. Immortal time bias was observed in a sensitivity analysis of meta-analysing risk-based preterm birth data. In descriptive summaries for stillbirth, congenital anomalies and maternal non-obstetric SAEs, no significant association with increased risk was found in any studies. All evidence was of very low certainty. Conclusions Evidence of very low certainty suggests that seasonal influenza vaccination during pregnancy is not associated with adverse birth outcomes or maternal non-obstetric SAEs. Appropriate control of confounding and temporal biases in future studies would improve the evidence base.
Open AccessSafety of influenza vaccination during pregnancy: a systematic review
Objective We conducted a systematic review to evaluate associations between influenza vaccination during pregnancy and adverse birth outcomes and maternal non-obstetric serious adverse events (SAEs), taking into consideration confounding and temporal biases. Methods Electronic databases (Ovid MEDLINE ALL, Embase Classic+Embase and the Cochrane Central Register of Controlled Trials) were searched to June 2021 for observational studies assessing associations between influenza vaccination during pregnancy and maternal non-obstetric SAEs and adverse birth outcomes, including preterm birth, spontaneous abortion, stillbirth, small-for-gestational-age birth and congenital anomalies. Studies of live attenuated vaccines, single-arm cohort studies and abstract-only publications were excluded. Records were screened using a liberal accelerated approach initially, followed by a dual independent approach for full-text screening, data extraction and risk of bias assessment. Pairwise meta-analyses were conducted, where two or more studies met methodological criteria for inclusion. The Grading of Recommendations, Assessment, Development and Evaluation approach was used to assess evidence certainty. Results Of 9443 records screened, 63 studies were included. Twenty-nine studies (24 cohort and 5 case–control) evaluated seasonal influenza vaccination (trivalent and/or quadrivalent) versus no vaccination and were the focus of our prioritised syntheses; 34 studies of pandemic vaccines (2009 A/H1N1 and others), combinations of pandemic and seasonal vaccines, and seasonal versus seasonal vaccines were also reviewed. Control for confounding and temporal biases was inconsistent across studies, limiting pooling of data. Meta-analyses for preterm birth, spontaneous abortion and small-for-gestational-age birth demonstrated no significant associations with seasonal influenza vaccination. Immortal time bias was observed in a sensitivity analysis of meta-analysing risk-based preterm birth data. In descriptive summaries for stillbirth, congenital anomalies and maternal non-obstetric SAEs, no significant association with increased risk was found in any studies. All evidence was of very low certainty. Conclusions Evidence of very low certainty suggests that seasonal influenza vaccination during pregnancy is not associated with adverse birth outcomes or maternal non-obstetric SAEs. Appropriate control of confounding and temporal biases in future studies would improve the evidence base.
- Open Access
- 31 March 2023
- Published by Oxford University Press (OUP) in Translational Behavioral Medicine
- Vol. 13 (7) , 442-452
Exploring research team members’ and trial participants’ perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview study
The SPIN-CHAT Program was designed to support mental health among individuals with systemic sclerosis (SSc; commonly known as scleroderma) and at least mild anxiety symptoms at the onset of COVID-19. The program was formally evaluated in the SPIN-CHAT Trial. Little is known about program and trial acceptability, and factors impacting implementation from the perspectives of research team members and trial participants. Thus, the propose of this follow-up study was to explore research team members’ and trial participants’ experiences with the program and trial to identify factors impacting acceptability and successful implementation. Data were collected cross-sectionally through one-on-one, videoconference-based, semi-structured interviews with 22 research team members and 30 purposefully recruited trial participants (Mage = 54.9, SD = 13.0 years). A social constructivist paradigm was adopted, and data were analyzed thematically. Data were organized into seven themes: (i) getting started: the importance of prolonged engagement and exceeding expectations; (ii) designing the program and trial: including multiple features; (iii) training: research team members are critical to positive program and trial experiences; (iv) offering the program and trial: it needs to be flexible and patient-oriented; (v) maximizing engagement: navigating and managing group dynamics; (vi) delivering a videoconference-based supportive care intervention: necessary, appreciated, and associated with some barriers; and (vii) refining the program and trial: considering modification when offered beyond the period of COVID-19 restrictions. Trial participants were satisfied with and found the SPIN-CHAT Program and Trial to be acceptable. Results offer implementation data that can guide the design, development, and refinement of other supportive care programs seeking to promote psychological health during and beyond COVID-19. The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program, a videoconference-based supportive care program, was designed to protect and enhance mental health in individuals affected by systemic sclerosis (commonly known as scleroderma) with at least mild anxiety symptoms during the COVID-19 pandemic. A trial was conducted to evaluate the SPIN-CHAT Program, and results were generally positive. However, important gaps in knowledge remained. Specifically, research team members’ and participants’ perceptions of SPIN-CHAT Trial acceptability (including satisfaction) and factors impacting implementation of the SPIN-CHAT Program had not yet been explored. To fill this gap, we conducted one-on-one, videoconference-based, semi-structured interviewed with 22 research team members and 30 purposefully recruited trial participants. Interviews sought to gain insights into research team members’ and trial participants’ experiences within the SPIN-CHAT Program, delivery preferences, and aspects that were/were not beneficial. Findings suggest research team members and participants valued the SPIN-CHAT Program and found the trial to be acceptable. Results also highlight important factors to consider when designing, developing, and/or refining videoconference-based supportive care programs.
- 31 March 2023
- Published by Oxford University Press (OUP) in Translational Behavioral Medicine
- Vol. 13 (7) , 442-452
Open AccessExploring research team members’ and trial participants’ perceptions of acceptability and implementation within one videoconference-based supportive care program for individuals affected by systemic sclerosis during COVID-19: a qualitative interview study
The SPIN-CHAT Program was designed to support mental health among individuals with systemic sclerosis (SSc; commonly known as scleroderma) and at least mild anxiety symptoms at the onset of COVID-19. The program was formally evaluated in the SPIN-CHAT Trial. Little is known about program and trial acceptability, and factors impacting implementation from the perspectives of research team members and trial participants. Thus, the propose of this follow-up study was to explore research team members’ and trial participants’ experiences with the program and trial to identify factors impacting acceptability and successful implementation. Data were collected cross-sectionally through one-on-one, videoconference-based, semi-structured interviews with 22 research team members and 30 purposefully recruited trial participants (Mage = 54.9, SD = 13.0 years). A social constructivist paradigm was adopted, and data were analyzed thematically. Data were organized into seven themes: (i) getting started: the importance of prolonged engagement and exceeding expectations; (ii) designing the program and trial: including multiple features; (iii) training: research team members are critical to positive program and trial experiences; (iv) offering the program and trial: it needs to be flexible and patient-oriented; (v) maximizing engagement: navigating and managing group dynamics; (vi) delivering a videoconference-based supportive care intervention: necessary, appreciated, and associated with some barriers; and (vii) refining the program and trial: considering modification when offered beyond the period of COVID-19 restrictions. Trial participants were satisfied with and found the SPIN-CHAT Program and Trial to be acceptable. Results offer implementation data that can guide the design, development, and refinement of other supportive care programs seeking to promote psychological health during and beyond COVID-19. The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program, a videoconference-based supportive care program, was designed to protect and enhance mental health in individuals affected by systemic sclerosis (commonly known as scleroderma) with at least mild anxiety symptoms during the COVID-19 pandemic. A trial was conducted to evaluate the SPIN-CHAT Program, and results were generally positive. However, important gaps in knowledge remained. Specifically, research team members’ and participants’ perceptions of SPIN-CHAT Trial acceptability (including satisfaction) and factors impacting implementation of the SPIN-CHAT Program had not yet been explored. To fill this gap, we conducted one-on-one, videoconference-based, semi-structured interviewed with 22 research team members and 30 purposefully recruited trial participants. Interviews sought to gain insights into research team members’ and trial participants’ experiences within the SPIN-CHAT Program, delivery preferences, and aspects that were/were not beneficial. Findings suggest research team members and participants valued the SPIN-CHAT Program and found the trial to be acceptable. Results also highlight important factors to consider when designing, developing, and/or refining videoconference-based supportive care programs.
- 1 February 2023
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 35 (2) , 95-114
Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total HADS for screening for major depression: A systematic review and individual participant data meta-analysis.
The seven-item Hospital Anxiety and Depression Scale Depression subscale (HADS-D) and the total score of the 14-item HADS (HADS-T) are both used for major depression screening. Compared to the HADS-D, the HADS-T includes anxiety items and requires more time to complete. We compared the screening accuracy of the HADS-D and HADS-T for major depression detection. We conducted an individual participant data meta-analysis and fit bivariate random effects models to assess diagnostic accuracy among participants with both HADS-D and HADS-T scores. We identified optimal cutoffs, estimated sensitivity and specificity with 95% confidence intervals, and compared screening accuracy across paired cutoffs via two-stage and individual-level models. We used a 0.05 equivalence margin to assess equivalency in sensitivity and specificity. 20,700 participants (2,285 major depression cases) from 98 studies were included. Cutoffs of ≥7 for the HADS-D (sensitivity 0.79 [0.75, 0.83], specificity 0.78 [0.75, 0.80]) and ≥15 for the HADS-T (sensitivity 0.79 [0.76, 0.82], specificity 0.81 [0.78, 0.83]) minimized the distance to the top-left corner of the receiver operating characteristic curve. Across all sets of paired cutoffs evaluated, differences of sensitivity between HADS-T and HADS-D ranged from -0.05 to 0.01 (0.00 at paired optimal cutoffs), and differences of specificity were within 0.03 for all cutoffs (0.02-0.03). The pattern was similar among outpatients, although the HADS-T was slightly (not nonequivalently) more specific among inpatients. The accuracy of HADS-T was equivalent to the HADS-D for detecting major depression. In most settings, the shorter HADS-D would be preferred. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 1 February 2023
- Published by American Psychological Association (APA) in Psychological Assessment
- Vol. 35 (2) , 95-114
Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total HADS for screening for major depression: A systematic review and individual participant data meta-analysis.
The seven-item Hospital Anxiety and Depression Scale Depression subscale (HADS-D) and the total score of the 14-item HADS (HADS-T) are both used for major depression screening. Compared to the HADS-D, the HADS-T includes anxiety items and requires more time to complete. We compared the screening accuracy of the HADS-D and HADS-T for major depression detection. We conducted an individual participant data meta-analysis and fit bivariate random effects models to assess diagnostic accuracy among participants with both HADS-D and HADS-T scores. We identified optimal cutoffs, estimated sensitivity and specificity with 95% confidence intervals, and compared screening accuracy across paired cutoffs via two-stage and individual-level models. We used a 0.05 equivalence margin to assess equivalency in sensitivity and specificity. 20,700 participants (2,285 major depression cases) from 98 studies were included. Cutoffs of ≥7 for the HADS-D (sensitivity 0.79 [0.75, 0.83], specificity 0.78 [0.75, 0.80]) and ≥15 for the HADS-T (sensitivity 0.79 [0.76, 0.82], specificity 0.81 [0.78, 0.83]) minimized the distance to the top-left corner of the receiver operating characteristic curve. Across all sets of paired cutoffs evaluated, differences of sensitivity between HADS-T and HADS-D ranged from -0.05 to 0.01 (0.00 at paired optimal cutoffs), and differences of specificity were within 0.03 for all cutoffs (0.02-0.03). The pattern was similar among outpatients, although the HADS-T was slightly (not nonequivalently) more specific among inpatients. The accuracy of HADS-T was equivalent to the HADS-D for detecting major depression. In most settings, the shorter HADS-D would be preferred. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
- 28 January 2023
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 46 (3) , 1-13
A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members
Explore trial participants’ and research team members’ perceptions of the impact of the videoconference-based, supportive care program (SPIN-CHAT Program) during early COVID-19 for individuals with systemic sclerosis (SSc). Data were collected cross-sectionally. A social constructivist paradigm was adopted, and one-on-one videoconference-based, semi-structured interviews were conducted with SPIN-CHAT Trial participants and research team members. A hybrid inductive-deductive approach and reflexive thematic analysis were used. Of the 40 SPIN-CHAT Trial participants and 28 research team members approached, 30 trial participants (Mean age = 54.9; SD = 13.0 years) and 22 research team members agreed to participate. Those who took part in interviews had similar characteristics to those who declined. Five themes were identified: (1) The SPIN-CHAT Program conferred a range of positive psychological health outcomes, (2) People who don’t have SSc don’t get it: The importance of SSc-specific programming, (3) The group-based format of the SPIN-CHAT Program created a safe space to connect and meet similar others, (4) The structure and schedule of the SPIN-CHAT Program reduced feelings of boredom and contributed to enhanced psychological health, (5) The necessity of knowledge, skills, and tools to self-manage SSc and navigate COVID-19. Participants’ and research team members’ perspectives elucidated SPIN-CHAT Program benefits and how these benefits may have been realized. Results underscore the importance of social support from similar others, structure, and self-management to enhance psychological health during COVID-19. clinicaltrials.gov (NCT04335279)
- 28 January 2023
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 46 (3) , 1-13
A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: perceptions of trial participants and research team members
Explore trial participants’ and research team members’ perceptions of the impact of the videoconference-based, supportive care program (SPIN-CHAT Program) during early COVID-19 for individuals with systemic sclerosis (SSc). Data were collected cross-sectionally. A social constructivist paradigm was adopted, and one-on-one videoconference-based, semi-structured interviews were conducted with SPIN-CHAT Trial participants and research team members. A hybrid inductive-deductive approach and reflexive thematic analysis were used. Of the 40 SPIN-CHAT Trial participants and 28 research team members approached, 30 trial participants (Mean age = 54.9; SD = 13.0 years) and 22 research team members agreed to participate. Those who took part in interviews had similar characteristics to those who declined. Five themes were identified: (1) The SPIN-CHAT Program conferred a range of positive psychological health outcomes, (2) People who don’t have SSc don’t get it: The importance of SSc-specific programming, (3) The group-based format of the SPIN-CHAT Program created a safe space to connect and meet similar others, (4) The structure and schedule of the SPIN-CHAT Program reduced feelings of boredom and contributed to enhanced psychological health, (5) The necessity of knowledge, skills, and tools to self-manage SSc and navigate COVID-19. Participants’ and research team members’ perspectives elucidated SPIN-CHAT Program benefits and how these benefits may have been realized. Results underscore the importance of social support from similar others, structure, and self-management to enhance psychological health during COVID-19. clinicaltrials.gov (NCT04335279)